{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:04Z","timestamp":1792081504555,"version":"4.4.0"},"reference-count":49,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) significantly impacts transplant outcomes, responsible for half of all deaths in the first 5\u00a0years after LT for HCC, with a 12\u201315\u2010month median overall survival after recurrence. Recent advances in post\u2010LT risk stratification and efficacy data of radical local treatments with curative intent support risk\u2010adapted tailored surveillance. To date, only immunosuppressive regimen minimisation has been recognised as a potential preventive measure, although the respective roles of calcineurin inhibitor minimisation and mTOR inhibitor introduction remain inconclusive. Retrospective studies highlight the considerable heterogeneity between patients with recurrent HCC after LT in terms of timing, anatomical distribution, and applicability of treatments. Selected patients may benefit in a durable manner from local approaches with a curative intent, while tyrosine kinase inhibitors remain the first line systemic treatments. The use of immune checkpoint inhibitors is a major challenge associated with major risks of graft rejection and related mortality, that should be evaluated in prospective clinical trials. The impact on recurrent HCC of recent changes of pre\u2010LT management, such as expanded selection criteria or the increasing use of downstaging strategies including post\u2010ICI LT, has not been evaluated yet. Recurrent HCC after LT is a major unmet need, calling for a prospective and multicentre effort to improve outcomes for this special population.<\/jats:p>","DOI":"10.1002\/ueg2.70078","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T14:04:07Z","timestamp":1751724247000},"page":"1069-1076","source":"Crossref","is-referenced-by-count":4,"title":["Recurrence of Hepatocellular Carcinoma After Liver Transplantation: The Blind Spot of HCC Management"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-8551","authenticated-orcid":false,"given":"M.","family":"Ningarhari","sequence":"first","affiliation":[{"name":"CHU Lille Maladies de l\u2019Appareil Digestif  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-244X","authenticated-orcid":false,"given":"G.","family":"Lassailly","sequence":"additional","affiliation":[{"name":"CHU Lille Maladies de l\u2019Appareil Digestif  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dharancy","sequence":"additional","affiliation":[{"name":"CHU Lille Maladies de l\u2019Appareil Digestif  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Hepatopancreatology and Digestive Oncology H\u00f4pital Universitaire de Bruxelles Universit\u00e9 Libre de Bruxelles  Brussels Belgium"},{"name":"Laboratory of Experimental Gastroenterology Universit\u00e9 Libre de Bruxelles  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-3934","authenticated-orcid":false,"given":"E.","family":"Tr\u00e9po","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Hepatopancreatology and Digestive Oncology H\u00f4pital Universitaire de Bruxelles Universit\u00e9 Libre de Bruxelles  Brussels Belgium"},{"name":"Laboratory of Experimental Gastroenterology Universit\u00e9 Libre de Bruxelles  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13358"},{"key":"e_1_2_9_3_1","article-title":"EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma","author":"Sangro B.","year":"2024","journal-title":"Journal of Hepatology"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.09.025"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.052"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.025"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619840221"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010014\u20104273\u20106"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000001894"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/lvt.0000000000000501"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2021.101.1.28"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20128"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000589"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000003117"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100445"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000001966"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5116"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/lvt.0000000000000145"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001297"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/lvt.0000000000000487"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001086"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20100012.2010.01212.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.08.068"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001746"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000004487"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104607"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.07.012"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17021"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16142"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000003196"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000002147"},{"key":"e_1_2_9_32_1","article-title":"Association Between Everolimus Combination Therapy and Cancer Risk After Liver Transplantation: A Nationwide Population\u2010Based Quasi\u2010Cohort Study","volume":"16","author":"Jang S. C.","year":"2025","journal-title":"American Journal of Transplantation"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15253"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000000965"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0217"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.12659\/aot.930383"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010024\u201016085\u2010z"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15811"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.038"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000550"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.026"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.01.001"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.26264"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000005240"},{"key":"e_1_2_9_45_1","unstructured":"Efficacy and Safety of Lenvatinib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation\u2014Bang\u20142023\u2014Cancer Medicine\u2014Wiley Online Library[Internet]. [cit\u00e9 14 janv 2025] https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5123."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184584"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000002955"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13897"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i45.5081"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010046"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:55:55Z","timestamp":1761137755000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/ueg2.70078"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.70078","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}